The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma

Multiple myeloma and its precursor plasma cell dyscrasias affect 3% of the elderly population in the US. Proteasome inhibitors are an essential part of several standard drug combinations used to treat this incurable cancer. These drugs interfere with the main pathway of protein degradation and lead...

Full description

Bibliographic Details
Main Authors: Laure Maneix, Melanie A. Sweeney, Sukyeong Lee, Polina Iakova, Shannon E. Moree, Ergun Sahin, Premal Lulla, Sarvari V. Yellapragada, Francis T. F. Tsai, Andre Catic
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
ubiquitin-proteasome system
mitoprotease
multiple myeloma
bortezomib
carfilzomib
drug resistance
Online Access:https://www.mdpi.com/2072-6694/13/4/843

Internet

https://www.mdpi.com/2072-6694/13/4/843

Similar Items